Tozorakimab, a new biologic treatment for COPD, has demonstrated rapid symptom reduction and sustained benefits in clinical trials, with 300 mg administered once every four weeks showing effectiveness regardless of blood eosinophil counts and marking the first biologic to reduce mucus plugging in COPD patients.
- Tozorakimab at 300 mg every four weeks produced rapid daily symptom reduction from the first dose in COPD patients
- The drug reduced mean segmental mucus plug score by 28% at week 52, a first-of-its-kind benefit among COPD biologics
- Benefits were sustained through week 52 and maintained through week 80 in long-term extension trials
- Results showed effectiveness regardless of blood eosinophil counts, offering broader patient applicability
- Data from three phase 3 trials (OBERON, TITANIA, and PROSPERO) were presented at CHEST 2026 Annual Meeting in Phoenix
A new round of analysis on three clinical trials has brought more positive evidence for tozorakimab as a treatment for patients with COPD.
The data were presented as three late-breaking presentations at the American College of Chest Physicians 2026 Annual Meeting (CHEST) in Phoenix.
According to a press release from AztraZeneca, manufacturer of tozorakimab, the analysis looked at the phase 3 OBERON and TITIANA trials as well as results from the ongoing long-term extension trial PROSPERO.
The news comes after the drug met its primary endpoints in OBERON and TITANIA earlier this year. Another long-term trial, MIRANDA, is also ongoing. The four studies are part of the LUNA program, which is aimed at evaluating the safety and efficacy of tozorakimab.
The new analysis of OBERON and TITANIA demonstrated that 300 mg of tozorakimab, administered once every four weeks, led to rapid reduction in daily symptoms from the first dose. Nominally significant benefits were sustained throughout the treatment period to week 52. The reductions were seen in patients regardless of blood eosinophil counts.
The full results from OBERON and TITANIA, “Tozorakimab to Prevent COPD Exacerbations,” were published in The New England Journal of Medicine.
PROSPERO is a long-term extension of OBERON and TITANIA, but with a different primary endpoint: the annualized rate of severe COPD exacerbations leading to hospitalizations and death in the primary population of smokers up to 104 weeks.
The results from the primary endpoint of former smokers showed a numerical, but not statistically significant, reduction in severe exacerbations. However, there was a nominally significant reduction in severe exacerbations in the overall population of former and current smokers.
PROSPERO results also showed that continued treatment with tozorakimab maintained the reduction in moderate and severe COPD exacerbations in former smokers and the overall population.
Further analysis of PROSPERO found that tozorakimab is the first biologic to reduce mucus plugging in a broad population of patients with COPD. The analysis showed that tozorakimab reduced the mean segmental mucus plug score by 28% from baseline at week 52. That reduction was maintained through week 80.
Henrik Watz, MD, LUNA program investigator, said the results show promise of a bright future for tozorakimab and those who suffer from COPD.
“Based on the totality of the data, I believe tozorakimab has the potential to be a groundbreaking step forward in the treatment of COPD,” said Dr. Watz, who is also principal investigator at Velocity Clinical Research in Ahrensburg, Germany, and professor of clinical research in respiratory medicine at Lubeck University.
